These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17187427)

  • 1. Enhancing hepatitis C treatment uptake and outcomes for injection drug users.
    Dore GJ
    Hepatology; 2007 Jan; 45(1):3-5. PubMed ID: 17187427
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.
    Jeffrey GP; MacQuillan G; Chua F; Galhenage S; Bull J; Young E; Hulse G; O'Neil G
    Hepatology; 2007 Jan; 45(1):111-7. PubMed ID: 17187435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C treatment for injection drug users: a review of the available evidence.
    Hellard M; Sacks-Davis R; Gold J
    Clin Infect Dis; 2009 Aug; 49(4):561-73. PubMed ID: 19589081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hepatitis C in Rhode Island: opportunities for improvement within and beyond the department of corrections.
    Berzin T; Allen S; Taylor L; Rich J; Feller E
    Med Health R I; 2002 Nov; 85(11):341-4. PubMed ID: 12462866
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
    Lucidarme D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B112-20. PubMed ID: 12180278
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection].
    Lozano Polo JL; Gutiérrez Mora E; Martínez Pérez V; Santamaría Gutiérrez J; Vada Sánchez J; Vallejo Correas JA
    Rev Clin Esp; 1997 Jul; 197(7):479-83. PubMed ID: 9411543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prisons, prisoners, and hepatitis C.
    Ferguson L; Batey R
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1184-6. PubMed ID: 20594243
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of chronic hepatitis C in active drug users.
    Davis GL; Rodrigue JR
    N Engl J Med; 2001 Jul; 345(3):215-7. PubMed ID: 11463020
    [No Abstract]   [Full Text] [Related]  

  • 9. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
    Dollarhide AW; Loh C; Leckband SG; Endow-Eyer R; Robinson S; Meyer JM
    J Clin Gastroenterol; 2007 Mar; 41(3):322-8. PubMed ID: 17426475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shall we treat all patients with hepatitis C, and if not, why? Certainly, injecting drug users must not be an exclusion criterion.
    Tillmann HL; Thompson AJ
    Digestion; 2008; 78(2-3):120-2. PubMed ID: 19023206
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of hepatitis C in injection drug users.
    Scott LD
    Am J Gastroenterol; 2005 Jan; 100(1):5-7. PubMed ID: 15654772
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders.
    Freedman K; Nathanson J
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):363-76. PubMed ID: 19344248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on hepatitis. Increased RBV dose for better HCV treatment response.
    Bernard EJ
    IAPAC Mon; 2006 Jan; 12(1):18. PubMed ID: 17249131
    [No Abstract]   [Full Text] [Related]  

  • 14. Injection drug users can be effectively treated for hepatitis C.
    Stancliff S
    Am Fam Physician; 2011 Mar; 83(6):647; author reply 648. PubMed ID: 21404974
    [No Abstract]   [Full Text] [Related]  

  • 15. Infection fighters. Hepatitis C and HIV.
    TreatmentUpdate; 2005; 17(1):7. PubMed ID: 17225318
    [No Abstract]   [Full Text] [Related]  

  • 16. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.
    Hagan H; Latka MH; Campbell JV; Golub ET; Garfein RS; Thomas DA; Kapadia F; Strathdee SA;
    Clin Infect Dis; 2006 Mar; 42(5):669-72. PubMed ID: 16447112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly acquired hepatitis C--many hurdles from diagnosis until treatment initiation.
    Wiegand J
    J Gastroenterol Hepatol; 2008 Dec; 23(12):1782-4. PubMed ID: 19120870
    [No Abstract]   [Full Text] [Related]  

  • 18. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
    Rance J; Newland J; Hopwood M; Treloar C
    Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination on the agenda for hepatitis C.
    Burki T
    Lancet Infect Dis; 2014 Jun; 14(6):452-3. PubMed ID: 24971446
    [No Abstract]   [Full Text] [Related]  

  • 20. Treating intravenous drug users with hepatitis C infection: an opportunity in some settings.
    Chong VH; Jamaludin AZ; Jacob AP; Jalihal A
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1121. PubMed ID: 16957520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.